Literature DB >> 9585796

Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects.

J K Lamba1, R K Dhiman, K K Kohli.   

Abstract

One hundred unrelated healthy North Indian subjects were phenotyped with respect to their ability to metabolize omeprazole to 5-hydroxyomeprazole. Each volunteer was requested to ingest 20 mg (57.9 mumol) omeprazole. Urine was collected for a period of 8 hours and the amount of 5-hydroxyomeprazole excreted was estimated by HPLC. Histogram, probit, and normal test variable plots showed the antimode value for the log hydroxylation index of omeprazole to be 1.7. Of 100 North Indian subjects, 11 demonstrated log hydroxylation index values more than 1.7. Thus it is inferred that the frequency of occurrence of poor metabolizers of omeprazole in North Indian subjects is 11% (95% confidence interval, 5% to 17%). From the Hardy-Weinberg Law it was computed that the frequency of occurrence of the mutant allele of hepatic CYP2C19 in the North Indian subjects was 0.33.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585796     DOI: 10.1016/S0009-9236(98)90037-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians.

Authors:  J Rosemary; C Adithan; N Padmaja; C H Shashindran; N Gerard; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2005-01-21       Impact factor: 2.953

3.  Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients.

Authors:  Kashif Ur Rehman; Tanveer Akhtar; Muhammad Farooq Sabar; Muhammad Akram Tariq
Journal:  Exp Ther Med       Date:  2015-05-14       Impact factor: 2.447

Review 4.  Implementing genotype-guided antithrombotic therapy.

Authors:  Richard L Seip; Jorge Duconge; Gualberto Ruaño
Journal:  Future Cardiol       Date:  2010-05

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Voriconazole potentiates warfarin-induced prothrombin time prolongation.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

7.  CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.

Authors:  Chonlaphat Sukasem; Ramaimon Tunthong; Montri Chamnanphon; Siwalee Santon; Thawinee Jantararoungtong; Napatrupron Koomdee; Santirhat Prommas; Apichaya Puangpetch; Prin Vathesatogkit
Journal:  Pharmgenomics Pers Med       Date:  2013-08-22

8.  Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Springerplus       Date:  2012-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.